Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654438 | 0.85 | IDO1 (0.50) | HSPA5IDO1 | |
| SCHEMBL839232 | 0.85 | GABRA1 (0.46) | CYP2D6 | |
| SCHEMBL27791324 | 0.85 | TRPA1 (0.39) | HSPA5IDO1TAAR1CYP1A1CYP1A2 | |
| SCHEMBL1005334 | 0.85 | ALDH1A1 (0.41) | HSPA5PNMTIDO1TAAR1TSHR | |
| SCHEMBL6632824 | 0.85 | APOBEC3G (0.48) | HSPA5TAAR1CYP2D6TSHRHIF1A | |
| SCHEMBL891102 | 0.85 | PNMT (0.50) | PNMTTAAR1DPP4CYP2A6 | |
| SCHEMBL525380 | 0.81 | — | — | |
| SCHEMBL321423 | 0.81 | ADRA2B (0.39) | TAAR1 | |
| SCHEMBL4420288 | 0.81 | TDP1 (0.44) | HSPA5TAAR1CYP2D6TSHRHIF1A | |
| SCHEMBL28470833 | 0.81 | TAAR1 (0.56) | TAAR1CYP1A2CYP2D6CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-10-30 | — | — | US | claimed |
| EP-1492534-B1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2008-06-25 | — | — | EP | claimed |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-06-30 | — | — | US | claimed |
| EP-1492534-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082288-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2003-10-09 | — | — | WO | claimed |
| US-5246932-A | Adenosine antagonist such as vasodilation | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-09-21 | — | — | US | claimed |
| EP-0515108-A2 | Azolo (1,3,5) triazines as adenosine antagonists | ZENECA LIMITED (GB) | 1992-11-25 | — | — | EP | claimed |
| EP-0471783-A1 | POLYMETHINE COMPOUNDS, AND POLYMER COMPOSITIONS CONTAINING THEM | EASTMAN KODAK COMPANY (US) | 1992-02-26 | — | — | EP | claimed |
| US-4994512-A | Photostabilizers for vecerage and food containers of polyesters or polycarbonate; ultraviolet radiation resistance | EASTMAN KODAK COMPANY (US) | 1991-02-19 | — | — | US | claimed |
| EP-0401128-A1 | Polymethine compounds and polymer compositions containing them | EASTMAN KODAK COMPANY (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1990013597-A1 | POLYMETHINE COMPOUNDS, AND POLYMER COMPOSITIONS CONTAINING THEM | EASTMAN KODAK COMPANY (US) | 1990-11-15 | — | — | WO | claimed |
| US-4252921-A | IMAGES HAVING GOOD WEAR RESISTANCE | EASTMAN KODAK COMPANY (US) | 1981-02-24 | — | — | US | claimed |
| US-4247474-A | POLYFUNCTIONAL ALKYLENE, CYCLOALKYLENE, OR ARYLENE DERIVATIVES; HYDROGEN CHLORIDE SALTS USED AS CURING AGENTS | HERCULES INCORPORATED (US) | 1981-01-27 | — | — | US | claimed |
| US-4202785-A | Polyesterionomers having utility in liquid electrographic developer compositions | EASTMAN KODAK COMPANY (US) | 1980-05-13 | — | — | US | claimed |
| US-12509585-B2 | Thermal conductive silicone composition | DUPONT TORAY SPECIALTY MATERIALS KABUSHIKI KAISHA (JP) | 2025-12-30 | — | — | US | disclosed |
| WO-2025079317-A1 | HYDROPHILIC COMPOSITION | 信越化学工業株式会社 | 2025-04-17 | — | — | WO | disclosed |
| CN-119301194-A | Hydrophilic composition | 信越化学工业株式会社 | 2025-01-10 | — | — | CN | disclosed |
| EP-0067308-A1 | Neutralizing layer for color transfer assemblages | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1982-12-22 | — | — | EP | disclosed |
| US-4252921-A | IMAGES HAVING GOOD WEAR RESISTANCE | EASTMAN KODAK COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| US-4202785-A | Polyesterionomers having utility in liquid electrographic developer compositions | EASTMAN KODAK COMPANY (US) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509585-B2 | Thermal conductive silicone composition | ILK, COL2A1, COL1A1 | HSPA5 1543/4885PNMT 1635/4885IDO1 3567/4885 |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | HSPA5 3437/4885PNMT 4634/4885IDO1 815/4885 |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | HDAC5, HDAC1, HDAC7 | HSPA5 2076/4885PNMT 3289/4885IDO1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.